73P Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the C... von Chan, A., Ruiz Borrego, M., Marx, G., Brufsky, A., Chien, A.J., Thirlwell, M.P., Trudeau, M.E., Bose, R., García Saenz, J.Á., Egle, D., Pistilli, B., Wassermann, J., Cheong, K.A., Semsek, D., Singer, C.F., Diprimeo, D., Foruzan, N., McCulloch, L.M., Barcenas, C.H.

Volltext

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial von Jhaveri, K., Eli, L.D., Wildiers, H., Hurvitz, S.A., Guerrero-Zotano, A., Unni, N., Brufsky, A., Park, H., Waisman, J., Yang, E.S., Spanggaard, I., Reid, S., Burkard, M.E., Vinayak, S., Prat, A., Arnedos, M., Bidard, F.-C., Loi, S., Crown, J., Bhave, M., Piha-Paul, S.A., Suga, J.M., Chia, S., Saura, C., Garcia-Saenz, J.Á., Gambardella, V., de Miguel, M.J., Gal-Yam, E.N., Rapael, A., Stemmer, S.M., Ma, C., Hanker, A.B., Ye, D., Goldman, J.W., Bose, R., Peterson, L., Bell, J.S.K., Frazier, A., DiPrimeo, D., Wong, A., Arteaga, C.L., Solit, D.B.

Volltext

Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial von Jhaveri, K, Eli, L.D, Wildiers, H, Hurvitz, S.A, Guerrero-Zotano, A, Unni, N, Brufsky, A, Park, H, Waisman, J, Yang, E.S, Spanggaard, I, Reid, S, Burkard, M.E, Vinayak, S, Prat, A, Arnedos, M, Bidard, F.-C, Loi, S, Crown, J, Bhave, M, Piha-Paul, S.A, Suga, J.M, Chia, S, Saura, C, Garcia-Saenz, J.A, Gambardella, V, de Miguel, M.J, Gal-Yam, E.N, Raphael, A, Stemmer, S.M, Ma, C, Hanker, A.B, Ye, D, Goldman, J.W, Bose, R, Peterson, L, Bell, J.S.K, Frazier, A, Diprimeo, D, Wong, A, Arteaga, C.L, Solit, D.B

Volltext

Supplementary Material for: Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without mTOR Inhibitors in Patients with Fibrolamellar Carcinoma von G.K., Abou-Alfa, T., Meyer, R.K.G., Do, S.A., Piha-Paul, J.S., Light, S., Sherrin, A., Yaqubie, A.C., O’Neill, J.J., Harding, R., Al-Rajabi, C.S., Denlinger, P., Cano, A.S., Cornelius, E.M., O'Reilly, D., DiPrimeo, L.D., Eli, J.D., Gordan, D.B., Solit

Volltext bestellen

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers von Harding, James J., Piha-Paul, Sarina A., Shah, Ronak H., Murphy, Jessica J., Cleary, James M., Shapiro, Geoffrey I., Quinn, David I., Braña, Irene, Moreno, Victor, Borad, Mitesh, Loi, Sherene, Spanggaard, Iben, Park, Haeseong, Ford, James M., Arnedos, Mónica, Stemmer, Salomon M., de la Fouchardiere, Christelle, Fountzilas, Christos, Zhang, Jie, DiPrimeo, Daniel, Savin, Casey, Duygu Selcuklu, S., Berger, Michael F., Eli, Lisa D., Meric-Bernstam, Funda, Jhaveri, Komal, Solit, David B., Abou-Alfa, Ghassan K.

Volltext

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial von Friedman, Claire F., D'Souza, Anishka, Bello Roufai, Diana, Tinker, Anna V., de Miguel, Maria, Gambardella, Valentina, Goldman, Jonathan, Loi, Sherene, Melisko, Michelle E., Oaknin, Ana, Spanggaard, Iben, Shapiro, Geoffrey I., ElNaggar, Adam C., Panni, Stefano, Ravichandran, Vignesh, Frazier, Aimee L., DiPrimeo, Daniel, Eli, Lisa D., Solit, David B.

Volltext